Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice

Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC). However, the survival benefit is short lived and survivals after progressive disease (PD) have not been well characterized. This study aimed to evaluate the survival predictors...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicine (Baltimore)
Hlavní autoři: Lee, I-Cheng, Chen, Yi-Tzen, Chao, Yee, Huo, Teh-Ia, Li, Chung-Pin, Su, Chien-Wei, Lin, Han-Chieh, Lee, Fa-Yauh, Huang, Yi-Hsiang
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2015
Témata:
4500
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4554055/
https://ncbi.nlm.nih.gov/pubmed/25860213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000688
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky